^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

COMPANY:
Lucence

i
Other names: Lucence | Lucence Diagnostics Pte Ltd. | Lucence Diagnostics Pte Ltd
Related tests:
Evidence

News

2ms
Lucence confirms comprehensive Medicare coverage for LiquidHALLMARK® and demonstrates sensitive detection of lung cancer biomarkers in prospective study (Lucence Press Release)
"Lucence announced its receipt of confirmation that Medicare coverage for its LiquidHALLMARK® liquid biopsy test applies for patients with all stages of advanced solid tumors. This confirmation marks a significant milestone in promoting access to personalized oncology care on a broader scale."
Medicare • Reimbursement
|
LiquidHALLMARK®
7ms
Interim results from LIQUIK prospective study released at WCLC 2023 (Lucence Press Release)
"Lucence announced that interim results for LIQUIK, a prospective international multicenter liquid biopsy study for lung cancer, will be reported at the IASLC 2023 World Conference on Lung Cancer (WCLC) on September 9-12, 2023...Key objectives are prospective comparisons of Lucence’s LiquidHALLMARK® amplicon-based assay to tissue-based next generation sequencing (NGS), as well as to an FDA-approved circulating tumor DNA (ctDNA) liquid biopsy test."
Clinical data
|
LiquidHALLMARK®
8ms
Lucence announces CPT PLA code granted to LiquidHALLMARK™ (Lucence Press Release)
"The American Medical Association (AMA) has granted a Current Procedural Terminology (CPT) Proprietary Laboratory Analyses (PLA) code for our LiquidHALLMARK™ liquid biopsy test. The CPT PLA code uniquely identifies the LiquidHALLMARK™ test for payors and providers, thus reducing administrative burdens and improving access."
Medicare • Reimbursement
|
LiquidHALLMARK®
9ms
Lucence and Innovent announce strategic collaboration on bile duct cancer (Lucence Press Release)
"Lucence...announced...a strategic collaboration with Innovent Biologics, Inc. to improve access of Hong Kong patients with advanced bile duct cancer (cholangiocarcinoma) to the FDA-approved targeted treatment Pemazyre® (pemigatinib)...Under the agreement, Innovent will sponsor Lucence’s LiquidMARK™ Bile Duct test for Hong Kong patients with a diagnosis of bile duct cancer who fulfil criteria."
Licensing / partnership
|
LiquidMARK™ Bile Duct test
11ms
Lucence showcases liquid biopsy tech for earlier cancer detection at 2023 ASCO Annual Meeting (Lucence Press Release)
"Lucence will present promising new data on earlier cancer detection based on AmpliMark, its amplicon-based next generation sequencing technology at the 59th Annual ASCO Meeting in Chicago, June 2-6, 2023."
Clinical data
|
AmpliMark™
11ms
Lucence launches LucenceINSIGHT to detect cancer earlier (Lucence Press Release)
"Lucence unveiled LucenceINSIGHT™, its pioneering multi-cancer early detection (MCED) blood test, at their US headquarters...Lucence is launching LucenceINSIGHT™, an MCED test first internationally and with a follow-up U.S. launch in Q3 2023. This ctDNA-based liquid biopsy test screens for 10 common cancers in one blood draw."
Launch
|
LucenceINSIGHT™
1year
Singapore’s Lucence secures US Medicare approval for its cancer tests (Business Times)
"...Lucence has secured approval for its Singapore-invented cancer tests from Medicare, a US government-funded healthcare insurance programme primarily for people aged 65 years and older...The programme covers about 64 million people in the US and will reimburse patients for using Lucence’s blood test, LiquidHallmark, to detect lung cancer. In the US, there are about 150,000 new cases a year of advanced lung cancer in patients aged 65 and above."
Medicare • Reimbursement
|
LiquidHALLMARK®
1year
Lucence announces Medicare reimbursement decision for LiquidHALLMARK® assay in lung cancer (Lucence Press Release)
"Lucence announced...that Palmetto GBA, a Medicare administrative contractor and leader in evaluating molecular diagnostic technology through its laboratory technology assessment group for the Molecular Diagnostics Services program (MolDX), has finalized a foundational Local Coverage Determination (LCD) for the LiquidHALLMARK assay. The LCD covers all nine NCCN guideline-recommended molecular biomarkers in advanced lung cancer patients using LiquidHALLMARK."
Medicare • Reimbursement
|
LiquidHALLMARK®
over1year
Lucence shares promising interim data from LIQUIK prospective study at ISLB 2022 (Lucence Press Release)
"Lucence...is sharing promising interim results from the prospective multicenter validation study of its LiquidHALLMARK ctDNA liquid biopsy assay for the detection of guideline-recommended biomarkers in metastatic lung cancer. Results from the study— LIQUIK, or Liquid Biopsy for Detection of Actionable Genomic Biomarkers in Patients with Advanced Non-small Cell Lung Cancer—were shared as part of a poster presentation at the 4th Annual Congress of the International Society of Liquid Biopsy in Miami, Florida."
Clinical data
|
LiquidHALLMARK®
over1year
Lucence taps Omnigen to distribute liquid biopsy tests in Turkey (Genomeweb)
"Precision oncology firm Lucence said Tuesday that it has entered a new partnership with laboratory diagnostics distributor Omnigen Medical Products to expand access to its liquid biopsy tests for cancer patients in Turkey...Under the terms of the agreement, Omnigen will market tests, including Lucence's LiquidHallmark next-generation sequencing assay, to Turkish hospitals and clinicians as part of its existing business as a distributor of genetic testing and molecular and pathological equipment."
Licensing / partnership
|
LiquidHALLMARK®
over1year
Lucence, National Cancer Centre Singapore to study liquid biopsy assay in prostate cancer (Genomeweb)
"Precision oncology company Lucence...has entered into a research collaboration with the National Cancer Centre Singapore to evaluate the company's LiquidHallmark assay for improving prostate cancer treatment in Asian men...The collaborators plan to conduct a prospective study to better define the clinical utility of LiquidHallmark in guiding treatment decisions and achieving therapy outcomes among men with metastatic castration-resistant prostate cancer."
Licensing / partnership • New trial
|
LiquidHALLMARK®
over1year
Local study demonstrates synergies of using blood-based liquid biopsies to complement tissue biopsies for lung cancer diagnosis (Lucence Press Release)
"Researchers from A*STAR’s Institute of Bioengineering and Bioimaging (IBB), in collaboration with Changi General Hospital (CGH) and Lucence...conducted the first local prospective study which demonstrated that a blood-based liquid biopsy can be used to complement the conventional tissue biopsy for lung cancer diagnosis...The study focuses on non-small cell lung cancer (NSCLC) and has shown that a liquid biopsy test could be used to extract relevant information for a preliminary diagnosis."
Clinical
almost2years
Lucence presents data at 2022 world conference on lung cancer (WCLC) supporting utility of amplicon-based liquid biopsy (Lucence Press Release)
"Lucence will present new data at the upcoming IASLC 2022 World Conference on Lung Cancer on August 6-9, 2022, highlighting novel applications of its ultrasensitive amplicon-based next generation sequencing technology in the detection and treatment of lungLucence recently announced the publication of a validation study for its flagship LiquidHALLMARK ctDNA Liquid Biopsy Assay. The study, published in PLOS ONE, establishes LiquidHALLMARK’s performance and identifies actionable biomarkers in 70% of lung cancer patients. In addition to showing high sensitivity of both LiquidHALLMARK and Lucence’s AmpliMark amplicon next-generation sequencing (NGS) platform, external validation with cobas® EGFR Mutation Test v2 for lung cancer specimens demonstrated an overall concordance of 84.00% with a 100% concordance rate for EGFR variants above 0.4% VAF. cancer."
Clinical data
|
cobas® EGFR Mutation Test v2 • LiquidHALLMARK®
almost2years
Lucence Showcases Promising Data on ctDNA and ctRNA Liquid Biopsy Assay for Lung Cancer at 2022 ASCO Annual Meeting (Lucence Press Release)
"In plasma samples from non-small cell lung cancer (NSCLC) patients that were either baseline driver-negative (by ctDNA) or treated with tyrosine kinase-inhibitors, the combined assay found 8.7% (9/103) more actionable fusions than ctDNA alone. Together ctRNA and ctDNA resulted in detection of 30 fusions compared to 21 when only ctDNA was tested, representing a 42.8% (9/21) increase in fusion-specific detection of the combined assay; additional fusions detected included BRAF, MET and NRG1 fusions."
Clinical data
almost2years
Lucence announces publication of validation study for LiquidHALLMARK ctDNA liquid biopsy assay (Lucence Press Release)
"Lucence, the precision oncology company pioneering ultrasensitive liquid biopsy tests, is announcing the recent publication of a study validating its LiquidHALLMARK ctDNA liquid biopsy assay in PLOS ONE, a peer-reviewed, open access scientific journal. The study results establish high sensitivity, specificity, accuracy and precision of LiquidHALLMARK, based on the AmpliMark amplicon-sequencing platform, and support compelling clinical applications for its use."
Clinical data
|
LiquidHALLMARK®
over2years
Lucence’s LiquidHALLMARK liquid biopsy assay expands to include cfRNA (Lucence Press Release)
"Lucence...is announcing the availability of an expanded version of its flagship LiquidHALLMARK liquid biopsy assay that includes both cell-free DNA (cfDNA) and cell-free RNA (cfRNA) profiling. LiquidHALLMARK cfDNA and cfRNA is currently available to US oncologists as a laboratory developed test and is being utilized by physicians at NCI-designated centers across the country."
Clinical
|
LiquidHALLMARK®
over2years
Lucence launches first liquid biopsy screening study in partnership with the VA Palo Alto Health Care System (Businesswire)
"In partnership with the VA Palo Alto Health Care System, precision oncology company Lucence is launching its first early detection study in the United States evaluating the use of its liquid biopsy technology in a screening context. The study, led by Rajesh Shah, MD, of the VA Palo Alto Healthcare System and Stanford University, will test the feasibility of using non-invasive liquid biopsy in patients at high-risk for lung cancer as a screening tool in combination with positron emission tomography–computed tomography (PET/CT)."
Licensing / partnership • Launch
over2years
Lucence, Veteran's Affairs Health Care System launch liquid biopsy screening study (Precision Medicine Online)
"Lucence and the VA Palo Alto Health Care System are launching a prospective observational study to evaluate the use of the sequencing-based LiquidHallmark liquid biopsy assay in a screening context...The study will compare the sensitivity and specificity of positron emission tomography-computed tomography (PET/CT) alone versus PET/CT in combination with LiquidHallmark in detecting lung cancer nodules between six and 20 millimeters in size, among high-risk patients with at least one lung nodule suspected of malignancy."
Licensing / partnership • New trial
|
LiquidHALLMARK®
over2years
AstraZeneca and Lucence Collaborate in South-East Asia to bring HRD Testing to Ovarian Cancer Patients to guide PARPi Treatment (Lucence Press Release)
"AstraZeneca Singapore and Lucence announced today that they have entered into an agreement to provide improved access to Homologous Recombination Deficiency (HRD) testing for newly-diagnosed advanced ovarian cancer patients in the South-East Asia (SEA) region...This partnership with Lucence accentuates AstraZeneca’s ongoing push to tap into the expertise of healthcare innovators to help those suffering from chronic conditions such as diabetes, heart disease and cancer."
Licensing / partnership